Smith, Moore & Co’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $987K | Sell |
16,276
-513
| -3% | -$29.9K | 0.07% | 211 |
|
|
2025
Q4 | $906K | Sell |
16,789
-2,598
| -13% | -$125K | 0.07% | 211 |
|
|
2025
Q3 | $874K | Sell |
19,387
-5,802
| -23% | -$271K | 0.07% | 228 |
|
|
2025
Q2 | $1.17M | Sell |
25,189
-1,262
| -5% | -$61.9K | 0.1% | 178 |
|
|
2025
Q1 | $1.61M | Sell |
26,451
-2,426
| -8% | -$141K | 0.15% | 140 |
|
|
2024
Q4 | $1.63M | Sell |
28,877
-959
| -3% | -$53.6K | 0.15% | 128 |
|
|
2024
Q3 | $1.54M | Sell |
29,836
-257
| -0.9% | -$12.1K | 0.15% | 131 |
|
|
2024
Q2 | $1.25M | Sell |
30,093
-2,060
| -6% | -$92.2K | 0.13% | 145 |
|
|
2024
Q1 | $1.74M | Sell |
32,153
-857
| -3% | -$43.7K | 0.19% | 112 |
|
|
2023
Q4 | $1.64M | Sell |
33,010
-21
| -0.1% | -$1.1K | 0.19% | 103 |
|
|
2023
Q3 | $1.86M | Sell |
33,031
-162
| -0.5% | -$9.93K | 0.25% | 82 |
|
|
2023
Q2 | $2.06M | Buy |
33,193
+1,057
| +3% | +$70.9K | 0.26% | 81 |
|
|
2023
Q1 | $2.23M | Buy |
32,136
+432
| +1% | +$30.5K | 0.3% | 69 |
|
|
2022
Q4 | $2.28M | Sell |
31,704
-556
| -2% | -$41.9K | 0.32% | 68 |
|
|
2022
Q3 | $2.29M | Sell |
32,260
-641
| -2% | -$46.5K | 0.35% | 61 |
|
|
2022
Q2 | $2.53M | Sell |
32,901
-1,667
| -5% | -$127K | 0.39% | 51 |
|
|
2022
Q1 | $2.52M | Sell |
34,568
-58
| -0.2% | -$3.89K | 0.34% | 64 |
|
|
2021
Q4 | $2.16M | Buy |
34,626
+1,250
| +4% | +$73.3K | 0.3% | 68 |
|
|
2021
Q3 | $1.98M | Buy |
33,376
+1,233
| +4% | +$81.2K | 0.3% | 66 |
|
|
2021
Q2 | $2.21M | Sell |
32,143
-308
| -0.9% | -$20.1K | 0.33% | 64 |
|
|
2021
Q1 | $2.05M | Buy |
32,451
+11,172
| +53% | +$695K | 0.33% | 65 |
|
|
2020
Q4 | $1.26M | Buy |
21,279
+499
| +2% | +$30.7K | 0.23% | 80 |
|
|
2020
Q3 | $1.25M | Buy |
20,780
+3,893
| +23% | +$234K | 0.26% | 75 |
|
|
2020
Q2 | $934K | Sell |
16,887
-3,252
| -16% | -$195K | 0.21% | 89 |
|
|
2020
Q1 | $1.12M | Buy |
20,139
+912
| +5% | +$55.7K | 0.3% | 67 |
|
|
2019
Q4 | $1.23M | Buy |
19,227
+615
| +3% | +$35.2K | 0.26% | 72 |
|
|
2019
Q3 | $944K | Sell |
18,612
-1,890
| -9% | -$88.8K | 0.21% | 90 |
|
|
2019
Q2 | $929K | Buy |
20,502
+1,181
| +6% | +$55K | 0.21% | 96 |
|
|
2019
Q1 | $970K | Buy |
19,321
+610
| +3% | +$30.4K | 0.23% | 87 |
|
|
2018
Q4 | $973K | Sell |
18,711
-897
| -5% | -$48.2K | 0.26% | 75 |
|
|
2018
Q3 | $1.22M | Buy |
19,608
+541
| +3% | +$32.1K | 0.28% | 71 |
|
|
2018
Q2 | $1.05M | Sell |
19,067
-5
| -0% | -$270 | 0.26% | 73 |
|
|
2018
Q1 | $1.21M | Buy |
19,072
+905
| +5% | +$58.2K | 0.32% | 61 |
|
|
2017
Q4 | $1.11M | Sell |
18,167
-471
| -3% | -$29.5K | 0.3% | 68 |
|
|
2017
Q3 | $1.19M | Buy |
18,638
+1,140
| +7% | +$66.6K | 0.34% | 58 |
|
|
2017
Q2 | $975K | Buy |
17,498
+178
| +1% | +$9.69K | 0.33% | 58 |
|
|
2017
Q1 | $942K | Sell |
17,320
-1,409
| -8% | -$77.3K | 0.34% | 52 |
|
|
2016
Q4 | $1.09M | Buy |
18,729
+5,905
| +46% | +$323K | 0.42% | 49 |
|
|
2016
Q3 | $692K | Buy |
12,824
+3,006
| +31% | +$193K | 0.28% | 70 |
|
|
2016
Q2 | $722K | Buy |
9,818
+951
| +11% | +$67.2K | 0.3% | 73 |
|
|
2016
Q1 | $566K | Buy |
8,867
+3,824
| +76% | +$241K | 0.24% | 86 |
|
|
2015
Q4 | $347K | Buy |
5,043
+501
| +11% | +$33.1K | 0.17% | 108 |
|
|
2015
Q3 | $269K | Buy |
4,542
+302
| +7% | +$19.2K | 0.15% | 126 |
|
|
2015
Q2 | $282K | Buy |
4,240
+1
| +0% | +$66 | 0.14% | 134 |
|
|
2015
Q1 | $273K | Buy |
+4,239
| New | +$265K | 0.14% | 133 |
|
Other funds holding BMY
VCM
VPM
Smith, Moore & Co's BMY Position: Q1 2026 in Review
Smith, Moore & Co reduced its Bristol-Myers Squibb (BMY) stake by 3.1% in Q1 2026, selling an estimated $29.9K and leaving 16,276 shares worth $987K. The position accounts for 0.07% of the portfolio, ranked #211.
Smith, Moore & Co first reported a position in BMY in Q1 2015 and has held it in 45 quarters since. The position peaked at $2.53M in Q2 2022. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Smith, Moore & Co held 16,276 shares of Bristol-Myers Squibb worth $987K as of Q1 2026.
- Smith, Moore & Co sold 513 Bristol-Myers Squibb shares in Q1 2026, an estimated $29.9K.
- Bristol-Myers Squibb made up 0.07% of Smith, Moore & Co's portfolio in Q1 2026, its #211 holding.
- Smith, Moore & Co first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 45 quarters since.
- Smith, Moore & Co's Bristol-Myers Squibb position peaked at $2.53M in Q2 2022.
- 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Smith, Moore & Co's 13F filing for Q1 2026, filed 5 May 2026.